T-Cell Engagers: The Off-the-Shelf Alternative to CAR-T

Why T-cells can't see cancer cells

T-cells can kill cancer cells. That's the basis of immunotherapy. But T-cells need to recognize their target, and cancer cells are often invisible to the immune system — they don't display the signals that would trigger a T-cell response.

CAR-T cell therapy solves this by engineering the patient's own T-cells. Doctors extract T-cells from the patient's blood, genetically modify them in a lab to express a chimeric antigen receptor (CAR) that recognizes a target on the cancer cell, expand them to large numbers, and infuse them back. The engineered T-cells now recognize the cancer. Some patients with aggressive blood cancers have stayed in remission for years after a single infusion.

But CAR-T has constraints. Manufacturing takes 3 to 6 weeks. Each dose is custom-built for one patient. Treatment costs $419,500 to $465,000 (Abecma from Bristol-Myers Squibb at $419,500; Carvykti from Johnson & Johnson/Legend at $465,000). It requires specialized certified centers. And patients can deteriorate while waiting for their cells to be manufactured.

How bispecific antibodies redirect T-cells to kill cancer

T-cell engager bispecific antibodies do the same job pharmacologically. One arm of the antibody binds a target on the surface of the cancer cell — BCMA on myeloma cells, CD20 on lymphoma cells, DLL3 on small cell lung cancer cells. The other arm binds CD3, a receptor present on all T-cells.

The bispecific physically brings the T-cell and the cancer cell together. Once in proximity, the T-cell forms an immune synapse with the cancer cell and activates. It releases cytotoxic granules — perforin and granzymes — that kill the cancer cell.

Because the bispecific is a manufactured drug rather than a patient-specific cell product, there is no extraction or manufacturing wait — treatment can begin within days. The trade-off: bispecifics need repeated dosing (weekly to monthly, ongoing), while CAR-T is a one-time infusion.

Why bispecific T-cell engagers took 29 years from concept to FDA approval

The concept was first demonstrated in 1985, when researchers fused two antibody fragments — one targeting a tumor cell, one targeting a T-cell receptor — and showed the resulting hybrid antibody could redirect T-cells to kill specific cells in culture (Staerz, Kanagawa & Bevan, Nature 1985). Translating that demonstration into an FDA-approved drug took 29 years. Three engineering problems kept the format stuck in preclinical labs.

The first was CD3 affinity tuning. Bind CD3 too strongly and T-cells activate uncontrollably, triggering severe cytokine release. Bind it too weakly and there is no killing. Most early candidates failed in animal studies before reaching humans.

The second was half-life. The original BiTE (Bispecific T-cell Engager) format — the platform developed by Munich-based Micromet — used two small antibody fragments connected by a peptide linker, total mass around 55 kilodaltons. The molecule was small enough to clear through the kidneys in two to three hours. Treatment required continuous intravenous infusion through a portable pump worn for 28 days at a time.

The third was manufacturing. The immune system builds symmetrical antibodies in which both arms bind the same target. Forcing two different arms to pair correctly inside a single molecule required protein engineering breakthroughs that didn't arrive until the late 1990s and 2000s.

The BiTE format itself was invented at Munich's LMU by immunologists Peter Kufer and Gert Riethmüller, who first described a bispecific antibody linking two single-chain fragments with a flexible peptide. Their technology was commercialized by Micromet, a Munich biotech that licensed and developed it. Patrick Baeuerle joined Micromet as Chief Scientific Officer in 1996 and shepherded the lead molecule — a CD19 × CD3 bispecific called blinatumomab — through nearly two decades of clinical development. Amgen acquired Micromet on January 26, 2012 for $1.16 billion ($11 per share) to obtain blinatumomab and the BiTE platform (Amgen press release, January 26, 2012).

Blincyto: the first FDA-approved T-cell engager (2014)

On December 3, 2014, the FDA granted accelerated approval to Amgen's Blincyto (blinatumomab) for relapsed or refractory B-cell acute lymphoblastic leukemia. It was the first bispecific T-cell engager approved anywhere. One arm bound CD19 on leukemia cells; the other bound CD3 on T-cells.

In the Phase 2 trial that supported approval, 42% of patients (77 of 185) achieved complete remission. The subsequent TOWER trial confirmed an overall survival benefit over chemotherapy, converting the accelerated approval to regular approval.

Blincyto used the original BiTE format described earlier. To maintain effective serum concentrations against the molecule's short half-life, the FDA prescribing information requires a continuous intravenous infusion at 9–28 mcg/day for 28 consecutive days per cycle, followed by a 14-day rest interval, administered through a programmable lockable portable pump. Patients wear the pump and a central-line connection around the clock for the full month of each cycle; hospitals built dedicated workflows for preparation, administration, and toxicity monitoring. A clinical review of the regimen described continuous-infusion administration as “cumbersome for all and, for some, completely prohibitive” (Zugmaier, Annals of Blood). That delivery burden — not the efficacy data — is widely credited with slowing the BiTE platform's industry uptake for nearly a decade, until full IgG-format bispecifics with weeks-long half-lives arrived in 2022.

Why no other T-cell engagers were approved for eight years

Several pharmaceutical companies that had been developing competing BiTE candidates quietly shelved or paused the format after watching Blincyto's commercial reception. From December 2014 to October 2022 — nearly eight years — no other bispecific-antibody T-cell engager reached FDA approval. (Immunocore's Kimmtrak, approved in January 2022, used a structurally different TCR-based format and is discussed below.)

The breakthrough came from a different format entirely: full-size IgG antibodies engineered to be bispecific. Two technical platforms made this possible. Genentech's "knobs-into-holes" engineering, first published in 1996 (Ridgway, Presta & Carter, Protein Eng 1996), reshaped the antibody's heavy-chain interface so each chain would lock into the other rather than pair with itself. Roche's CrossMab platform extended the approach by swapping light-chain domains to prevent mispairing (Schaefer et al., PNAS 2011). Denmark-based Genmab's DuoBody platform took a third route, generating bispecifics by mixing two parent antibodies and triggering controlled Fab-arm exchange (Labrijn et al., Nat Protoc 2014).

The result: full IgG-format bispecifics with a plasma half-life of around 21 days instead of hours. Subcutaneous injection once a week or every two weeks. No pump. Johnson & Johnson's Tecvayli, approved in October 2022, was the first IgG-format T-cell engager. Nine more followed in three years — and four of them landed in the same disease as the established CAR-T therapies, setting up the most direct head-to-head competition the modality has faced.

Multiple myeloma: four T-cell engagers competing with two CAR-T therapies

Multiple myeloma is the only disease where bispecifics and CAR-T compete directly for the same patient. Both classes are approved for relapsed/refractory disease after four prior lines of therapy. Both, in most cases, target the same protein: BCMA (B-cell maturation antigen) on myeloma cells. The clinical question for an oncologist is no longer “is immunotherapy an option,” but “which immunotherapy fits this patient.” That is the comparison the rest of the brief works through.

J&J's Talvey targets a different protein - GPRC5D instead of BCMA - which matters because patients who progress after BCMA-directed therapy may still respond to a different target.

T-cell engager vs CAR-T: response rates, cost, and durability in myeloma

A 2024 meta-analysis comparing CAR-T and bispecific T-cell engagers as third-line or later treatments for multiple myeloma found that CAR-T achieved higher pooled response rates: 83% overall response rate versus 65% for bispecifics, and 54% complete response versus 35%.

Durability data also favors CAR-T at this point. Five-year follow-up from the CARTITUDE-1 trial showed that 33% of patients treated with J&J/Legend's Carvykti remained progression-free at five years after a single infusion. The longest bispecific follow-up data (Tecvayli, MajesTEC-1) shows a median progression-free survival of 11.3 months.

Per-dose, bispecifics look much cheaper than CAR-T. Cumulatively, the gap closes faster than the table suggests. Tecvayli's WAC is roughly $9,500 per weekly dose, about $39,500 per month, or $427,000 over twelve months (CADTH reimbursement review, 2024) — within the $419,500–$465,000 band of a single CAR-T infusion. After roughly twelve months of continuous treatment, bispecific spend crosses CAR-T's one-time cost.

Those pooled response figures also smooth over wide differences between individual drugs. The two approved CAR-Ts diverge sharply — Carvykti's registered response rates and durability are well above sibling Abecma. Among bispecifics, the second-generation Lynozyfic and the GPRC5D-targeting Talvey have moved closer to CAR-T response depth than first-generation Tecvayli or Elrexfio.

Cytokine release syndrome: why bispecific CRS is mostly grade 1-2

Both CAR-T and bispecific T-cell engagers can cause cytokine release syndrome (CRS) - a systemic inflammatory response triggered when large numbers of T-cells activate simultaneously and release cytokines. Symptoms range from fever (grade 1) to hypotension, hypoxia, and organ dysfunction (grade 3+).

CRS occurs with both approaches, but the severity profile differs. With CAR-T, CRS rates of 59-90% are reported, with 12-29% reaching grade 3 or higher. With bispecifics, CRS rates are similar in frequency (50-72% for Tecvayli) but heavily weighted toward grade 1 and 2 - in MajesTEC-1, 50% of patients had grade 1 CRS and 21% had grade 2, with a single case of grade 3.

Bispecifics use step-up dosing to manage this risk. The first doses are given at low levels and gradually increased, allowing T-cell activation to build incrementally rather than all at once. CRS events cluster during these initial step-up doses and become infrequent at the target dose. Tocilizumab, an IL-6 receptor blocker, is used to treat CRS events when they occur.

That risk profile shapes how bispecifics are administered in practice. Tecvayli's FDA label requires patients to be hospitalized for 48 hours after each of the two step-up doses, and the drug is dispensed only through the TECVAYLI and TALVEY REMS program. Once a patient clears the step-up window without complication, weekly (or, since 2024, biweekly) dosing can move to the outpatient setting.

Want the next brief? Subscribe - free, every two weeks.

T-cell engagers in solid tumors: Kimmtrak and Imdelltra

Most approved T-cell engagers target blood cancers - leukemia, lymphoma, myeloma - where the cancer cells circulate in the blood and are accessible to both T-cells and the bispecific. Solid tumors are harder. The tumor microenvironment suppresses immune responses, and getting T-cells into a dense tumor mass is a different challenge than engaging them in the bloodstream.

Two T-cell engagers have reached solid tumors. Immunocore's Kimmtrak (tebentafusp), approved in January 2022, targets gp100 on uveal melanoma cells - but uses a different format: a T-cell receptor (TCR) fused to an anti-CD3 domain, which can recognize intracellular peptides presented on HLA molecules, not just surface proteins. It's restricted to patients who are HLA-A*02:01-positive (roughly half of the population).

Amgen's Imdelltra (tarlatamab), targeting DLL3 on small cell lung cancer cells, received accelerated approval in May 2024 and full approval in November 2025 for extensive-stage SCLC after platinum-based chemotherapy. DLL3 is expressed on 80-90% of SCLC tumors but minimally on normal tissue, making it a favorable target.

Ten FDA-approved T-cell engagers (2014–2025)

Bispecific antibodies span a broader category than T-cell engagers alone. Roche's Hemlibra bridges two clotting factors to treat hemophilia; Roche's Vabysmo blocks two pathways at once for retinal disease; J&J's Rybrevant blocks both EGFR and MET in lung cancer. The ten approvals below are the subset whose two arms specifically redirect T-cells.

In 2014, there was one approved bispecific T-cell engager. By end-2025, ten — eight in the last three years alone. The myeloma space has four bispecifics competing head-to-head with two CAR-Ts for the same patient population. Tecvayli alone generated approximately $549 million in 2024 (J&J 2024 results, PharmaLive); the broader CAR-T market exceeds $5 billion annually.

The two classes are now being studied in combination, typically CAR-T followed by bispecific consolidation. Early signals are encouraging but follow-up is short, and no combination regimen is FDA-approved yet.